Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000950170-22-018296
Filing Date
2022-09-09
Accepted
2022-09-09 16:17:46
Documents
14
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A fstx-20220331.htm   iXBRL 10-Q/A 98364
2 EX-31.1 fstx-ex31_1.htm EX-31.1 21978
3 EX-31.2 fstx-ex31_2.htm EX-31.2 21289
  Complete submission text file 0000950170-22-018296.txt   305818

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fstx-20220331_lab.xml EX-101.LAB 23599
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fstx-20220331_pre.xml EX-101.PRE 14428
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fstx-20220331.xsd EX-101.SCH 2383
8 EXTRACTED XBRL INSTANCE DOCUMENT fstx-20220331_htm.xml XML 7494
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

EIN.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-37718 | Film No.: 221236402
SIC: 2834 Pharmaceutical Preparations